Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy

Overall survival and recurrence-free survival of patients with CR-mRECIST-only and CR-RECISTv1.1 were excellent, and 6 of 7 patients with CR-mRECIST-only who underwent surgical conversion therapy had pathological CR. Despite potential limitations, these findings support the use of mRECIST in the context of immunotherapy for clinical decision-making. When considering ICI discontinuation, treatment for at least 6 months beyond CR seems advisable.

Authors

Institutions

Publication Details

Journal
Hepatology
Published
2024-11-21
DOI
https://doi.org/10.1097/hep.0000000000001163
Citations
27
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
9.98
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy

David James Pinato, Michael Schultheiß, Arndt Weinmann, Ignazio Piseddu et al.
27 citations
Hepatology
Hepatocellular Carcinoma Treatment and Prognosis
9.98
article

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy

David James Pinato, Michael Schultheiß, Arndt Weinmann, Ignazio Piseddu, Florian Paul Reiter, Alexander B. Philipp, Najib Ben Khaled, Pei‐Chang Lee, Katharina Lampichler, Anna Lena Saborowski, Antonio D’Alessio, Fabian Finkelmeier, Katharina Pomej, Xiao Yuan, Florian Hucke, Rudolf E Stauber, Masatoshi Kudo, Jiang Guo, Bertram Bengsch, Long Cheng, Caterina Vivaldi, Neehar D. Parikh, Bernhard Scheiner, Anwaar Saeed, Andreas Geier, Joao Gorgulho, Fanpu Ji, Melanie Bathon, Vera Himmelsbach, Hung‐Wei Wang, Matthias Pinter, Gianluca Masi, Birgit Schwacha-Eipper, Marino Venerito, Lorenza Rimassa, Hong Jae Chon, Friedrich Sinner, Yi‐Hsiang Huang, Jeroen Dekervel, Beodeul KANG, Arndt Vogel, Mohamed Bouattour, Michael A Trauner, Frederik Peeters, Angela Djanani, Giulia Tesini, Juraj Prejac, Anja Krall, Lorenz Balcar, Valentina Zarka, Naoshi Nishida, Jean‐François Dufour, Xu Gao, Kornelius Schulze, Johann von Felden, Iuliana‐Pompilia Radu, Markus Peck-Radosavljevic, Gordan Adžić
article en
27 citations

Abstract

Overall survival and recurrence-free survival of patients with CR-mRECIST-only and CR-RECISTv1.1 were excellent, and 6 of 7 patients with CR-mRECIST-only who underwent surgical conversion therapy had pathological CR. Despite potential limitations, these findings support the use of mRECIST in the context of immunotherapy for clinical decision-making. When considering ICI discontinuation, treatment for at least 6 months beyond CR seems advisable.

HepatologyVol. 81(6)
University of Pisa (IT), Goethe University Frankfurt (DE), University of Bern (CH), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), Humanitas University (IT), University Hospital Centre Zagreb (HR), Innsbruck Medical University (AT), National Yang Ming Chiao Tung University (TW), Universität Hamburg (DE), University of Freiburg (DE), University of Pittsburgh (US), University of Zagreb (HR), Capital Medical University (CN), China Medical University (TW), Universität Innsbruck (AT), Johannes Gutenberg University Mainz (DE), Medical University of Graz (AT), University of Michigan (US), Hôpital Beaujon (FR), University Hospital of Bern (CH), Toronto General Hospital (CA), Princess Margaret Cancer Centre (CA), Taipei Veterans General Hospital (TW), LMU Klinikum (DE), Medizinische Hochschule Hannover (DE), Klinikum Klagenfurt (AT), University Medical Center of the Johannes Gutenberg University Mainz (DE), Assistance Publique – Hôpitaux de Paris (FR), University Medical Center Hamburg-Eppendorf (DE), Universitätsklinikum Würzburg (DE), China Medical University Hospital (TW), Second Affiliated Hospital of Xi'an Jiaotong University (CN), University Hospital Frankfurt (DE), CHA University Bundang Medical Center (KR), University Hospital Magdeburg (DE), CHA University (KR), Beijing Ditan Hospital (CN), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), Imperial College London (GB), Medical University of Vienna (AT), Ludwig-Maximilians-Universität München (DE), Xi'an Jiaotong University (CN), Kindai University (JP), Otto-von-Guericke-Universität Magdeburg (DE), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 1%
Hepatocellular Carcinoma Treatment and Prognosis
9.98
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.